News

News

Celogics highlights its iPSC derived Cardiomyocytes at the Society of Toxicology (SOT) Annual Meeting and Tox Expo

관리자

view : 1287

Published DATE: April 20th, 2022


Celogics highlights its iPSC derived Cardiomyocytes

at the Society of Toxicology (SOT) Annual Meeting and Tox Expo


 

 

Seattle, WA., April 20th, 2022 - Celogics, a leading developer in iPSC derived Cardiomyocytes, showcased their unique high-quality cells during the Society of Toxicology (SOT) Annual Meeting and ToxExpo in San Diego, California from March 27-31, 2022. 


Celo.Cardiomyocytes are high-quality human iPSC-derived cardiomyocytes developed by NEXEL, well known as Cardiosight-S, and exclusively licensed to Celogics for global distribution. These cells are derived from induced Pluripotent Stem Cells (iPSCs) using proprietary protocols which optimize the user experience by prioritizing purity, reproducibility, and electrophysiology.

 

“Increasingly, use of iPSC derived cells and tissues is a must-have during every stage of the drug discovery pipeline." said Jin Chang, Chief Operating Officer of Celogics. "Our unique innovations bring new levels of precision and consistency to in vitro biology, to accelerate the development of safer, more effective treatments." 

 

 

Celogics plans to continue to build its pipeline fully able to manufacture different kinds of iPSC-derived cell products for US and global markets. Currently, Celogics is focused on the development of skeletal myocytes, following up with the new optimized 3D culture & tissue-engineering application use Celo.Cardiomyocytes 3D Media. 

 

For more information, please visit www.celogics.com or follow the company on Twitter @celogics(link: https://twitter.com/celogics) or LinkedIn(https://www.linkedin.com/company/celogics-seattle)

 

 

 

About Celogics – www.celogics.com
Celogics brings together experts in cell biology and iPSC cell manufacturing to develop next-generation iPSC cell products for the life sciences research market. The company was established in November 2021 to serve the needs of the life sciences research community by providing high-quality iPSC-derived cell products from a U.S.-based manufacturing and fulfilment center located in the Seattle metropolitan area.

Please enter your password first.

CloseConfirm

  • logoCONTACT

    Contact Information

    • Address: 8F, 55 Magokdong-ro, Gangseo-gu, Seoul, Republic of Korea(07802)

    • Business Registration No.: 109-86-37282
    • CEO: Choongseong Han

    • Tel: +82-2-2088-8886
    • Fax: +82-2-2088-8884
    • E-mail: support@nexel.co.kr